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original article
The N363S polymorphism in the 
glucocorticoid receptor gene: 
effects on visceral fat assessed by 
abdominal computed tomography
Polimorfismo N363S do gene do receptor de glucocorticoide: efeito 
sobre a adiposidade visceral medida pela tomografia computadorizada
Cintia Cercato1, Alfredo Halpern1, Eliana S. T. Frazzatto2, Izabel 
Cristina Guazzelli2, Sandra Mara Ferreira Villares3 
AbstrAct
Objective: To verify whether N363S polymorphism of the glucocorticoid receptor-gene can be as-
sociated to visceral fat by CT scan in obese individuals, and the impact of this variant on metabo-
lic profile. Methods: The N363S variant was screened in 295 Brazilians, 195 were obese and 100 
presented normal weight. Based on genotype, obese N363S SNP carriers were paired with obe-
se wild-type subjects. This group was submitted to a CT scan and metabolic profile assessment. 
Results: Ten subjects were found to be heterozygous for the variant (A/G genotype frequency 
3.4%), 8 (4.1%) obese and 2 (2.0%) non-obese. No differences were reported for visceral adipo-
sity area (145.8 ± 49.9 vs.147.7 ± 48.8 cm2; p = 0.92) based on CT scan results but N363S SNP 
carriers showed a proneness to unfavorable metabolic changes. Conclusion: The N363S poly-
morphism prevalence is low in the Brazilian population, although its presence may contribute 
to the worsening of individuals’ metabolic profiles. Arq Bras Endocrinol Metab. 2009;53(2):288-292.
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resumo
Objetivo: Verificar se a presença do polimorfismo N363S do gene do receptor de glucocorticoi-
de estaria associada, em indivíduos obesos, à presença de adiposidade visceral pela tomogra-
fia computadorizada, e sobre o impacto desta variante genética no perfil metabólico. Métodos: 
A variante N363S do receptor do glicocorticoide foi verificada em um grupo de 295 indivíduos 
brasileiros, sendo 295 obesos e 100 com peso normal. Com base na genotipagem, os indi-
víduos obesos carreadores do polimorfismo N363S foram pareados com obesos normais. O 
grupo com polimorfismo foi submetido a exames de tomografia computadorizada abdominal 
e laboratoriais para a caracterização de seu perfil metabólico. Resultados: Dez indivíduos eram 
heterozigotos para a variante AG (3,4%), sendo oito obesos (4,1%) e dois não-obesos (2%). 
Não foram encontradas diferenças na quantidade de adiposidade visceral (145,8 ± 49,9 versus 
147,7 ± 48,8 cm2; p = 0,92) baseados no TC de abdômen. No entanto, os indivíduos carreadores 
do N363S SNP (single nucleotide polymorphism) apresentaram tendência a perfil metabólico 
desfavorável. Conclusão: O polimorfismo N363S do gene do receptor de glucocorticoide teve 
prevalência baixa na população estudada. A sua presença pode contribuir para a deterioração 
do perfil metabólico desses indivíduos. Arq Bras Endocrinol Metab. 2009;53(2):288-292.
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IntroDuctIon
Some obesity phenotypes – mainly those with abdom-inal adiposity – report clear characteristics of hyper-
cortisolism despite keeping serum cortisol levels within 
normal ranges (1,2). Most glucocorticoid action is car-
ried out through cortisol binding with an intracellular 
protein – the glucocorticoid receptor (GR) (3). The GR 
is part of the Type 1 subclass of nuclear receptors (4). 
The gene that codifies the GR (NR3C1) is located on 
the long arm of chromosome 5, in the 5q31-q32 region. 
GR expression level and receptor hormone binding af-
finity are the main determinants of tissue sensitivity (3). 
Recent data have suggested that GR phosphorylation 
may determine specificity to target receptors, interac-
tion with co-factors, cellular localization, and receptor 
stability (5). In 1997, Koper and cols. (6) described a 
GR polymorphism located at nucleotide position 1220 
(AAT to AGT), resulting in a change of asparagine into 
serine at codon 363 (N363S SNP) in the GR transacti-
vation domain. The presence of a new serine site in the 
transcription-activating amino-terminal region could 
lead to phosphorylation increase, as well as to higher 
receptor activity. Recently, examination of this poly-
morphism by microarray analysis showed that there are 
significant differences between wild-type GR and the 
N363S SNP in their ability to regulate gene expression 
selectively (7). Several of these genes may define the link 
between the N363S SNP and the human disease. In a 
Dutch study, a group of 216 elderly individuals were 
examined for the N363S polymorphism gene, and 13 
heterozygotes (6% of the group) were identified. Inter-
estingly, these carriers exhibited an increased sensitivity 
to exogenously administered glucocorticoids as well as 
an increased insulin response and increased body mass 
index (BMI) (8). Other studies also associated the pres-
ence of the N363S variant with body weight increase by 
analyzing BMI in a population of Australians of British 
origin (9), obese individuals in Italy (10), and diabetics 
in France (11). The same association could not be found 
in Danish individuals (12), or Swedish males (13).
Hypercortisolism patients present visceral obesity as 
a marked feature, although BMI in the same individu-
als is not always higher. Higher sensitivity to glucocorti-
coids may also be a predominant influence on abdominal 
adiposity distribution, as demonstrated by Dobson and 
cols., 2001 (14), who showed the association between 
N363S polymorphism and waist-hip ratio in men. How-
ever, that has not been proven by other studies, which 
also used only anthropometric measures for the assess-
ment of body fat distribution (10,13). Nowadays, it has 
also been demonstrated that the best method for the 
assessment of visceral adiposity is abdominal computed 
tomography (CT) scan (15) – not used in any study with 
carriers of this kind of polymorphism. The purpose of 
this study was to verify whether N363S polymorphism 
could be associated to visceral adiposity when assessed 
by abdominal CT scan on phenotypes associated with a 
metabolic syndrome such as insulin resistance, systemic 
arterial hypertension, increased levels of plasminogen 1 
activator inhibitor (PAI-1).
methoDs 
study Population
This study was approved by the Ethics Committee and 
all participants signed informed consent form. The assess-
ment included 295 individuals, of whom 195 are obese, 
and 100 are of normal weight according to BMI values. In 
the obese individuals (n = 195) group, 168 were females 
(86.1%) and 27 were males (13.9%). All participants were 
healthy individuals, in the age range of 18-55 years, and 
BMI ≥ 30 kg/m2 and < 40 kg/m2, with central distribu-
tion of adiposity (abdominal circumference ≥ 80 cm and 
waist-hip ratio > 0.8 in women, and abdominal circumfer-
ence ≥ 94 cm and waist-hip ratio > 0.95 in men). Individ-
uals of Asian ancestry or those reporting serious systemic 
conditions or persons with a history of systemic use of 
glucocorticoid in the previous 5 years were excluded. 
Genetic analysis 
Genomic DNA was extracted from peripheral blood 
samples by standard procedures. The N363S SNP was 
examined by a restriction fragment length polymorphism 
(RFLP) technique following polymerase chain reaction 
(PCR) amplification with primers 5’-TGCCATTTCTGT-
TCATGGTG-3’ (forward) and 5’-CTGAACTTCCCT-
GGTCGAAC-3’ (reverse). PCR conditions were initial 
denaturation at 94 ºC for 4 min, and 35 cycles at 94 ºC 
for denaturation, 58 ºC for annealing and 72 ºC for ex-
tension, each step lasting 1 min, with a final extension of 
7 min at 72 ºC. Amplification yielded a 210-bp fragment 
that contained two Tsp509I restriction sites (117+74+19 
bp) for the A-allele (N363) and only one (117+93 bp) for 
the G-allele (363S). Following enzymatic digestion, PCR 
products were resolved on 3% agarose gel electrophoresis 
and visualized by ethidium bromide staining.  
Glucocorticoid receptor and visceral fat
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
290 Arq Bras Endocrinol Metab. 2009;53/2
study protocol
All individuals were submitted to genetic analysis for the 
identification of N363S SNP. Based on genotype identi-
fication, N363S SNP obese carriers were carefully paired 
with non-carriers, at a 1:5 ratio following gender, race, 
age group, body weight, height and BMI, and were sub-
mitted to regional body fat measurements with CT scans, 
in addition to analysis of metabolic parameters such as 
glycemia, insulin, HOMA-IR, total cholesterol and frac-
tions, triglycerides, APOB, blood pressure and PAI-1.
In order to determine intra-abdominal and abdominal 
subcutaneous adiposity, a CT scan was carried out follow-
ing the technique standardized by Sjöstrom and Kvist in 
1988 (16). Plasma glucose level was determined by Roche 
Cobas Integra Model, through colorimetric enzyme as-
say, using hexokinase. Serum insulin concentration was 
determined by radio immunoassay by Linco Reseach, 
Inc. (USA) HI-14K. Analysis of insulin resistance was 
carried out through the homeostasis model assessment 
(HOMA) using the following formula: insulin resistance 
(IR) = insulin (µU/mL) x glucose (mmol/L)/22.5 (17). 
Total cholesterol (TC), HDL-C and plasma triglyceride 
(TG) levels were determined by COBAS MIRA auto-
mated system (F. Hoffmann-La Roche, Basel, Switzer-
land), by Roche’s commercial enzyme kits (Mannheim, 
Germany). PAI-1 plasma concentration was determined 
by IMUNOBIND Plasma PAI-1 ELISA using the CPT 
85400 kit by American Diagnostica Inc. (USA). 
statistical analysis
Results were expressed as mean ± standard deviation 
(SD) for quantitative variables. Absolute and relative 
frequencies were calculated for qualitative variables. 
Student’s t-test was used for equality hypothesis be-
tween averages in both groups. Fisher’s exact test was 
used for group homogeneity testing compared to ra-
tios. The significance level used for testing was 5%. 
results
A group of 295 individuals was examined for the N363S 
polymorphism, and 10 heterozygotes were identified 
(A/G genotype frequency was 3.4%; G-allele frequency 
was 1.7%). The obese individuals presented a double 
frequency of N363S SNP as compared to normal body 
weight individuals (Table 1). Waist, waist-hip, abdominal 
visceral adiposity (VA) and abdominal subcutaneous adi-
posity (SA), as well as the ratio VA/SA were compared be-
tween N363S SNP carriers and their paired controls, and 
no differences were found between the groups (Table 2). 
Metabolic parameters between N363S SNP carriers 
and paired non-carriers can be found in Table 3. In pa-
tients with N363S SNP a tendency to higher insulin re-
sistance by HOMA-IR assessment, higher levels of sys-
tolic blood pressure (SBP) and lower HDL-cholesterol 
levels was noted.  
table 2. Demographic and anthropometric characteristics according to genotype
N363/363S 
(genotype 
AG)
N363/N363
(genotype 
AA)
P
Subjects 8 40
Females 100% 100%
Age (years) 35.0 ± 7.9 33.8 ± 6.3 0.64
Body weight (kg) 88.6 ± 7.0 88.9 ± 7.2 0.93
Height (m) 1.59 ± 0.04 1.58 ± 0.04 0.96
BMI (kg/m2) 35.3 ± 2.4 35.4 ± 2.6 0.88
Fat mass (kg) 38.2 ± 3.7 36.9 ± 5.2 0.51
Fat mass (%) 43.1 ± 2.9 41.4 ± 3.8 0.25
Abdominal subcutaneous area (cm2) 479.3 ± 78.8 470.7 ± 101.2 0.82
Abdominal visceral area (cm2) 145.8 ± 49.9 147.7 ± 48.8 0.92
VA/SA Ratio 0.32 ± 0.14 0.33 ± 0.13 0.82
(mean ± SD)
table 1. Genotype frequencies according to BMI levels
BMI N363/N363
(genotype AA)
N363/363S 
(genotype AG)
< 25 kg/m2 98 (98.0%) 2 (2.0%)
≥ 30 kg/m2 187 (95.9%) 8 (4.1%)
Total population 285 (96.6%) 10 (3.4%)
table 3. Metabolic profile according to genotype
N363/363S
(genotype AG)
N363/N363
(genotype AA)
P
Subjects 8 48
Glucose (mg/dL) 88.0 ± 10.4 87.0 ± 8.3 0.52
HOMA-IR score 8.0 ± 3.2 6.6 ± 2.1 0.07
Total cholesterol (mg/dL) 174.8 ± 35.2 171.9 ± 23.0 0.82
HDL-cholesterol (mg/dL) 47.2 ± 13.6 42.0 ± 5.3 0.08
LDL-cholesterol (mg/dL) 104.5 ± 32.7 103.2 ± 21.8 0.92
Triglycerides (mg/dL) 115.5 ± 48.5 133.8 ± 65.7 0.36
APO B (mg/dL) 98.3 ± 20.2 90.4 ± 22.5 0.36
PAI-1 (mg/mL) 51.5 ± 6.7 51.7 ± 7.4 0.94
SBP (mmHg) 125.0 ± 10.7 117.0 ± 11.8 0.08
DBP (mmHg) 84.4 ± 11.2 79.5 ± 7.8 0.14
SI conversion factors: to convert serum glucose to mmol/L, multiply by 0.0555; total, HDL, and LDL 
cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.
Glucocorticoid receptor and visceral fat
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DIscussIon
In this population the A/G genotype frequency was 
3.4%: one of the lowest described for this type of poly-
morphism when compared to other distinct popula-
tions. The prevalence of this type of polymorphism has 
ranged between 3.9% and 9.3% for Caucasian popula-
tions of European origin (8-14), and has reached 19.8% 
for Australian individuals in Sidney (18). On the other 
hand, a recent description has reported extremely low 
frequency for this polymorphism in South Asian indi-
viduals living in England (19). Therefore, it seems there 
is some variation in polymorphism prevalence based on 
ethnic background. This study did not include Asian 
ancestry individuals, which could contribute to low 
polymorphism prevalence in our environment. How-
ever, high miscegenation in our country (Brazil) makes 
the analysis of ethnic influence on individuals’ geno-
types more difficult to be carried out.
GR’s N363S SNP has been associated with obe-
sity, but few studies have assessed the association with 
body adiposity distribution. In 2001, Dobson and cols. 
(14) reported increased waist-hip ratio between poly-
morphism carriers and non-carriers. A CT scan is the 
golden standard to determine visceral adiposity levels. 
This is the only study in literature to have assessed the 
association between N363S SNP and visceral adiposity 
through abdominal CT scan. Study results have shown 
no differences in abdominal visceral adiposity levels 
between polymorphism carriers as compared to paired 
non-carriers. The fact that no association was found may 
be an indication that the G-allele has little influence on 
visceral adiposity deposits in the Brazilian population 
at least at baseline. Perhaps some interventions – such 
as use of glucocorticoids at pharmacological dosing, or 
exposure to fat rich diets – may show differences in vis-
ceral adiposity levels in N363S SNP carriers. 
Other studies have shown that excess of cortisol is 
associated with insulin resistance (20,21). There are 
different techniques to assess insulin sensitivity (22,23). 
This study assessed insulin resistance through HO-
MA-IR, which has reported positive correlation with 
hyperinsulinemic euglycemic clamp (24). The present 
study has shown a tendency of higher insulin resistance 
through HOMA in N363S SNP carriers. 
Hypercortisolism patients presenting different 
changes in the metabolism of lipoproteins, including in-
creased plasma triglyceride levels, reduced HDL-choles-
terol levels, and increased APO B levels (25) have been 
reported. This study has detected a tendency towards 
lower HDL-cholesterol levels in N363S SNP carriers. 
In 1999, Fraser and cols. (26) investigated the associa-
tion between cortisol and cardiovascular risk factors in 
a Scottish population and found a significant inverse re-
lationship between cortisol and HDL-cholesterol. The 
author suggested cortisol may affect peripheral choles-
terol metabolism due to changes in HDL-cholesterol 
formation. The 363S allele may lead to lower HDL-
cholesterol levels through that mechanism. 
It has been described that adipocytes secrete PAI-1 
(27). The present study has found that obese patients 
presented quite high PAI-1 levels, but no differences 
were found when comparing polymorphism carriers 
and non-carriers. PAI-1 secretion is known to be higher 
at omental adiposity deposits – even after a dexametha-
sone stimulus (28). No difference in visceral adiposity 
levels between N363S SNP carriers and non-carriers 
was detected by the present study. Therefore, this may 
have contributed to the fact that no differences in PAI-1 
serum levels were found between the groups. 
Glucocorticoid in excess may lead to systemic hyper-
tension and cardiovascular adverse effects (29). This study 
has shown a tendency for SBP higher levels in N363S SNP 
carriers. The mechanisms through which glucocorticoids 
cause hypertension are not yet fully understood. Cortisol 
may directly increase vascular resistance and intravascular 
volume, thus increasing blood pressure (30). However, 
such salt and water retention mechanism as a result of 
glucocorticoid action seems to be induced by cortisol 
binding to type 1 mineralocorticoid renal receptors. The 
other glucocorticoid-induced blood pressure increase 
mechanism is indirect, resulting from insulin resistance. 
It is known that insulin resistance sponsors hyperten-
sion, especially as a result of sympathetic nervous activity, 
thus causing higher vascular resistance and higher water 
retention, thus contributing to blood pressure increase 
(31). Study data – showing a tendency to higher blood 
pressure levels in addition to higher insulin resistance in 
N363S SNP carriers – suggest both phenomena may be 
associated in the study population. 
Therefore, N363S SNP carriers in this population 
showed proneness to unfavorable metabolic changes, 
such as increased insulin resistance, increased blood 
pressure levels, and decreased HDL-cholesterol levels, 
irrespective of visceral adiposity increase. 
To conclude, the impact of this polymorphism is 
small in the study population as prevalence is only 3.4%, 
although its presence may contribute to the worsening 
of an individual’s metabolic profile. 
Glucocorticoid receptor and visceral fat
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